Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study)

INTRODUCTION: Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved to treat rheumatoid arthritis (RA). This study aimed to investigate patients’ characteristics, prescription patterns, effectiveness, and treatment persistence in patients receiving baricitinib in real-world practice in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández-Cruz, Blanca, Rosas, José, Díaz-Torné, César, Belzunegui, Joaquín, García-Vicuña, Rosario, Inciarte-Mundo, José, Pons, Ana, Millán, Ana M., Jeria-Navarro, Sicylle, Valero, Jesús A., García-Castañeda, Noelia, Valero, Cristina, Llorente, Irene, Calvo, Alberto, Díaz-Cerezo, Silvia, Núñez, Mercedes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964893/
https://www.ncbi.nlm.nih.gov/pubmed/35041155
http://dx.doi.org/10.1007/s40744-021-00423-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964893/
https://www.ncbi.nlm.nih.gov/pubmed/35041155
http://dx.doi.org/10.1007/s40744-021-00423-8

Ejemplares similares